Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements about the results of its PALISADE-2 trial of fasedienol [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from April 1, 2024, to December 16, 2025, with a deadline for lead plaintiff appointments set for March 16, 2026 [2]. - The complaint alleges that Vistagen made false and misleading statements regarding the success of its drug candidate, creating a false impression of a successful Phase 3 trial [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. for the period between April 1, 2024, and December 16, 2025, due to alleged misleading statements regarding the company's drug fasedienol [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided investors with overly positive information about the development and commercialization of fasedienol, an investigational drug for social anxiety disorder [5]. - Defendants allegedly made false and misleading statements while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to artificially inflated stock prices [6]. Group 2: Investor Information - Investors who purchased Vistagen common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - The complaint against Vistagen alleges violations of federal securities laws due to false or misleading statements regarding the Phase 3 PALISADE-3 trial of fasedienol for treating social anxiety disorder [2] Group 1: Company Performance - On December 17, 2025, Vistagen announced that its PALISADE-3 study did not meet its primary efficacy endpoint, failing to show statistically significant improvement in anxiety reduction compared to placebo [3] - Following the announcement, Vistagen's stock price dropped by $3.50, a decline of 80.27%, closing at $0.86 [3] Group 2: Legal Proceedings - The lead plaintiff in the class action is the investor with the largest financial interest in the case, who will oversee the litigation on behalf of the class [4] - Any member of the class can apply to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [4] Group 3: Whistleblower Information - The law firm Faruqi & Faruqi encourages individuals with information regarding Vistagen's conduct, including whistleblowers and former employees, to come forward [5]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. for the period between April 1, 2024, and December 16, 2025, due to alleged misleading statements regarding the company's drug fasedienol [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided investors with overly positive information about the development and commercialization of fasedienol, an investigational drug for social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6]. - Investors are alleged to have purchased Vistagen common stock at artificially inflated prices due to these misleading statements, resulting in damages when the true information became public [6]. Group 2: Class Action Participation - Investors who purchased Vistagen Therapeutics common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action has been filed against Vistagen Therapeutics, Inc. for allegedly misleading investors regarding the viability of its Phase 3 trial study of fasedienol, leading to significant financial losses for shareholders [1][2]. Group 1: Allegations and Trial Results - Robbins LLP is investigating allegations that Vistagen Therapeutics misled investors about the success of its Phase 3 PALISADE-3 trial of fasedienol, which was intended for treating social anxiety disorder [2]. - On December 17, 2025, Vistagen announced that the PALISADE-3 trial did not show a statistically significant improvement on its primary endpoint, leading to a dramatic stock price decline from $4.36 to $0.86, a drop of over 80% [3]. Group 2: Class Action Participation - Shareholders who purchased Vistagen's common stock between April 1, 2024, and December 16, 2025, may be eligible to participate in the class action and can contact Robbins LLP to serve as lead plaintiff [1][4]. - Participation in the class action is not mandatory for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropsychiatric and neurological disorders [1].

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. on behalf of purchasers of its common stock between April 1, 2024, and December 16, 2025, due to misleading statements regarding the company's drug fasedienol and its clinical trials [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided investors with overly positive information about the development and commercialization of fasedienol, an investigational drug for social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6]. - Investors are eligible for compensation without any out-of-pocket fees through a contingency fee arrangement if they purchased Vistagen common stock during the class period [2][3]. Group 2: Legal Representation - The Rosen Law Firm, which has a strong track record in securities class actions, is representing the investors and encourages them to select qualified counsel [4]. - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly [3][7].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period†). Vistagen is a clinical-stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegati. ...

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, inclusive. For more information, submit a form at Vistagen Therapeutics, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@ ...

LOS ANGELES--(BUSINESS WIRE)---- $VTGN--VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm. ...

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) securities between April 1, 2024 and December 16, 2025. The Complaint alleges that Defendants provided overwhelmingly positive statements to investors while ...